Cargando…

Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations

IMPORTANCE: X-linked retinitis pigmentosa (XLRP) is a severe cause of early-onset RP in male individuals, characterized by degeneration of photoreceptors, an extinguished electroretinogram, and vision loss. OBJECTIVE: To assess the duration of improvements in retinal sensitivity associated with a si...

Descripción completa

Detalles Bibliográficos
Autores principales: von Krusenstiern, Lenore, Liu, Jiajun, Liao, Eileen, Gow, James A., Chen, Guo, Ong, Tuyen, Lotery, Andrew J., Jalil, Assad, Lam, Byron L., MacLaren, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912164/
https://www.ncbi.nlm.nih.gov/pubmed/36757689
http://dx.doi.org/10.1001/jamaophthalmol.2022.6254
_version_ 1784885147659665408
author von Krusenstiern, Lenore
Liu, Jiajun
Liao, Eileen
Gow, James A.
Chen, Guo
Ong, Tuyen
Lotery, Andrew J.
Jalil, Assad
Lam, Byron L.
MacLaren, Robert E.
author_facet von Krusenstiern, Lenore
Liu, Jiajun
Liao, Eileen
Gow, James A.
Chen, Guo
Ong, Tuyen
Lotery, Andrew J.
Jalil, Assad
Lam, Byron L.
MacLaren, Robert E.
author_sort von Krusenstiern, Lenore
collection PubMed
description IMPORTANCE: X-linked retinitis pigmentosa (XLRP) is a severe cause of early-onset RP in male individuals, characterized by degeneration of photoreceptors, an extinguished electroretinogram, and vision loss. OBJECTIVE: To assess the duration of improvements in retinal sensitivity associated with a single, subretinal injection of cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy after vitrectomy surgery in the dosed eye over 12 months in part 1 of the Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS) study, compared with untreated fellow eyes and eyes from the untreated subgroup from the Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) study. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the XIRIUS and XOLARIS studies. Part 1 of the XIRIUS study was a phase 1, dose-escalation study of 18 male participants 18 years or older enrolled between March 8, 2017, and October 16, 2018, with genetically confirmed RPGR-variant XLRP with active disease and best-corrected visual acuity better than or equal to light perception (cohort 1), 34 to 73 letters (20/40 to 20/200 Snellen equivalent; cohorts 2-3), or greater than or equal to 34 letters (better than or equal to 20/200 Snellen equivalent; cohorts 4-6). Participants from the noninterventional, multicenter, global, prospective XOLARIS clinical study who met the inclusion and exclusion criteria of part 1 of XIRIUS were included as a comparator group (n = 103). Safety assessments included all XIRIUS participants; post hoc associations of retinal sensitivity assessments in XIRIUS only included the 12 participants receiving the 4 highest doses of cotoretigene toliparvovec. Data were analyzed on June 30, 2021. MAIN OUTCOMES AND MEASURES: Incidence of dose-limiting toxicities (DLTs), treatment-emergent adverse events, changes from baseline in retinal sensitivity (as assessed by macular integrity assessment microperimetry), retinal sensitivity response (achievement of ≥7-dB improvement from baseline at ≥5 of 16 central loci), and low-luminance visual acuity were assessed over 24 months. RESULTS: A total of 18 participants (mean [SD] age, 31.9 [9.4] years; male, 100%) were enrolled and completed the XIRIUS study. A subgroup of 103 participants (mean [SD] age, 30.8 [11.4] years; male, 100%) from the XOLARIS study was included. Administration of the 4 highest doses of cotoretigene toliparvovec (n = 12) among the 18 XIRIUS participants was associated with early improvements in retinal sensitivity. One of 103 untreated participants (1%) in the XOLARIS subgroup achieved improved retinal sensitivity at month 12. No DLTs were noted at any dose, and serious adverse events of reduced visual acuity (n = 2) and noninfective retinitis (n = 1) occurred. CONCLUSIONS AND RELEVANCE: Results suggest that early and sustained improvements in retinal sensitivity and low-luminance visual acuity in some participants through 12 months support consideration of additional clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: XIRIUS: NCT03116113; XOLARIS: NCT04926129
format Online
Article
Text
id pubmed-9912164
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-99121642023-02-11 Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations von Krusenstiern, Lenore Liu, Jiajun Liao, Eileen Gow, James A. Chen, Guo Ong, Tuyen Lotery, Andrew J. Jalil, Assad Lam, Byron L. MacLaren, Robert E. JAMA Ophthalmol Original Investigation IMPORTANCE: X-linked retinitis pigmentosa (XLRP) is a severe cause of early-onset RP in male individuals, characterized by degeneration of photoreceptors, an extinguished electroretinogram, and vision loss. OBJECTIVE: To assess the duration of improvements in retinal sensitivity associated with a single, subretinal injection of cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy after vitrectomy surgery in the dosed eye over 12 months in part 1 of the Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS) study, compared with untreated fellow eyes and eyes from the untreated subgroup from the Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) study. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the XIRIUS and XOLARIS studies. Part 1 of the XIRIUS study was a phase 1, dose-escalation study of 18 male participants 18 years or older enrolled between March 8, 2017, and October 16, 2018, with genetically confirmed RPGR-variant XLRP with active disease and best-corrected visual acuity better than or equal to light perception (cohort 1), 34 to 73 letters (20/40 to 20/200 Snellen equivalent; cohorts 2-3), or greater than or equal to 34 letters (better than or equal to 20/200 Snellen equivalent; cohorts 4-6). Participants from the noninterventional, multicenter, global, prospective XOLARIS clinical study who met the inclusion and exclusion criteria of part 1 of XIRIUS were included as a comparator group (n = 103). Safety assessments included all XIRIUS participants; post hoc associations of retinal sensitivity assessments in XIRIUS only included the 12 participants receiving the 4 highest doses of cotoretigene toliparvovec. Data were analyzed on June 30, 2021. MAIN OUTCOMES AND MEASURES: Incidence of dose-limiting toxicities (DLTs), treatment-emergent adverse events, changes from baseline in retinal sensitivity (as assessed by macular integrity assessment microperimetry), retinal sensitivity response (achievement of ≥7-dB improvement from baseline at ≥5 of 16 central loci), and low-luminance visual acuity were assessed over 24 months. RESULTS: A total of 18 participants (mean [SD] age, 31.9 [9.4] years; male, 100%) were enrolled and completed the XIRIUS study. A subgroup of 103 participants (mean [SD] age, 30.8 [11.4] years; male, 100%) from the XOLARIS study was included. Administration of the 4 highest doses of cotoretigene toliparvovec (n = 12) among the 18 XIRIUS participants was associated with early improvements in retinal sensitivity. One of 103 untreated participants (1%) in the XOLARIS subgroup achieved improved retinal sensitivity at month 12. No DLTs were noted at any dose, and serious adverse events of reduced visual acuity (n = 2) and noninfective retinitis (n = 1) occurred. CONCLUSIONS AND RELEVANCE: Results suggest that early and sustained improvements in retinal sensitivity and low-luminance visual acuity in some participants through 12 months support consideration of additional clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: XIRIUS: NCT03116113; XOLARIS: NCT04926129 American Medical Association 2023-02-09 2023-03 /pmc/articles/PMC9912164/ /pubmed/36757689 http://dx.doi.org/10.1001/jamaophthalmol.2022.6254 Text en Copyright 2023 von Krusenstiern L et al. JAMA Ophthalmology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License.
spellingShingle Original Investigation
von Krusenstiern, Lenore
Liu, Jiajun
Liao, Eileen
Gow, James A.
Chen, Guo
Ong, Tuyen
Lotery, Andrew J.
Jalil, Assad
Lam, Byron L.
MacLaren, Robert E.
Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations
title Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations
title_full Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations
title_fullStr Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations
title_full_unstemmed Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations
title_short Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations
title_sort changes in retinal sensitivity associated with cotoretigene toliparvovec in x-linked retinitis pigmentosa with rpgr gene variations
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912164/
https://www.ncbi.nlm.nih.gov/pubmed/36757689
http://dx.doi.org/10.1001/jamaophthalmol.2022.6254
work_keys_str_mv AT vonkrusenstiernlenore changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT liujiajun changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT liaoeileen changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT gowjamesa changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT chenguo changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT ongtuyen changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT loteryandrewj changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT jalilassad changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT lambyronl changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations
AT maclarenroberte changesinretinalsensitivityassociatedwithcotoretigenetoliparvovecinxlinkedretinitispigmentosawithrpgrgenevariations